home / stock / kzia / kzia news


KZIA News and Press, Kazia Therapeutics Limited From 03/21/24

Stock Information

Company Name: Kazia Therapeutics Limited
Stock Symbol: KZIA
Market: NASDAQ
Website: kaziatherapeutics.com

Menu

KZIA KZIA Quote KZIA Short KZIA News KZIA Articles KZIA Message Board
Get KZIA Alerts

News, Short Squeeze, Breakout and More Instantly...

KZIA - Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases PR Newswire SYDNEY , March 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is ...

KZIA - Kazia announces presentation of new data at AACR Annual Meeting

Kazia announces presentation of new data at AACR Annual Meeting PR Newswire SYDNEY , March 13, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both i...

KZIA - Kazia concludes Phase 1 study for paxalisib early due to promising data

2024-02-21 10:31:03 ET More on Kazia Kazia Therapeutics falls after announcing $2M direct offering Kazia stock jumps after proposed license deal for paxalisib outside oncology Financial information for Kazia Read the full article on Seeking Alpha For ...

KZIA - Kazia Therapeutics Reaches Primary Endpoint and Concludes Clinical Trial Early

2024-02-21 08:38:39 ET DENVER, Colo., 21 Feb, 2024 (www.247marketnews.com)- Kazia Therapeutics Limited (NASDAQ: KZIA ) reported an early conclusion, based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial, on its investig...

KZIA - Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint PR Newswire Paxalisib plus Radiotherapy Data Shows Promise for Treating Patients with PI3K Pathway Mutation Brain Metastases SYDNEY , Feb. 21, 2024 /PRNewswi...

KZIA - KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS PR Newswire SYDNEY , Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive...

KZIA - Expected US Company Earnings on Thursday, January 4th, 2024

Novonix Limited (NVNXF) is expected to report for quarter end 2023-12-31 MedAvail Holdings Inc. (MDVL) is expected to report for Q3 2023 Nobility Homes, Inc. (NOBH) is expected to report for quarter end 2023-10-31 Walgreens Boots Alliance Inc. (WBA) is expected to report $0.66 for Q1 ...

KZIA - Expected US Company Earnings on Thursday, December 28th, 2023

Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...

KZIA - Expected US Company Earnings on Thursday, December 21st, 2023

Enel Spa ADR (ENLAY) is expected to report for Q3 2023 LEG Immobilien SE Registered Shares (LEGIF) is expected to report for Q3 2023 G. Willi-Food International Ltd. (WILC) is expected to report for Q3 2023 Worthington Steel Inc. (WS) is expected to report $0.15 for Q2 2024 Sonic ...

KZIA - Kazia Therapeutics files to sell 591,697 ADSs for holders

2023-12-15 17:36:27 ET More on Kazia Kazia Therapeutics falls after announcing $2M direct offering Kazia stock jumps after proposed license deal for paxalisib outside oncology Historical earnings data for Kazia Financial information for Kazia For furt...

Previous 10 Next 10